Husnu Efendi, Prof
Kocaeli University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Husnu Efendi, Prof as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:34 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06843382 · Real-world Experience of Oral Agents On Fatigability in Multiple SclerosisTC Erciyes University · not yet recruiting · Multiple Sclerosis · study chair
- Ph3NCT03283397 · A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMSBosnalijek D.D · terminated · Multiple Sclerosis, Relapsing-Remitting · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:34 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Perioperative Nivolumab in Resectable Lung Cancer.N Engl J Med · 2024535 citationsRCR 59.3
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.N Engl J Med · 2024176 citationsRCR 20.7
- Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.J Thorac Oncol · 202367 citationsRCR 3.7
- Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.Chin Med J (Engl) · 201724 citationsRCR 1.0
- Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.Nat Cancer · 202619 citationsRCR 9.5
- Erosion protection benefits of stabilized SnF2 dentifrice versus an arginine-sodium monofluorophosphate dentifrice: results from in vitro and in situ clinical studies.Clin Oral Investig · 201716 citationsRCR 1.4
- Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity.J Transl Med · 201912 citationsRCR 0.4
- 12 citationsRCR 2.6
- Progression of Gastrointestinal Injury During Antiplatelet Therapy After Percutaneous Coronary Intervention: A Secondary Analysis of the OPT-PEACE Randomized Clinical Trial.JAMA Netw Open · 20237 citationsRCR 0.9
- The erosion protection efficacy of a stabilized stannous fluoride dentifrice: An in situ randomized clinical trial.Am J Dent · 20196 citationsRCR 0.7